HAHeleen H. Van Acker

Heleen H. Van Acker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heleen H. Van Acker has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Evelien Smits

    Center for Oncological Research, University of Antwerp, 2610 Antwerp, Belgium

    6 shared publications
  • Sébastien Anguille

    Division of Hematology, Antwerp University Hospital, Edegem, Belgium

    5 shared publications
  • Viggo F. Van Tendeloo

    Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium

    4 shared publications
  • Eva Lion

    Laboratory of Experimental Hematology, Vaccine & Infectious Disease institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

    3 shared publications
  • Viggo F. I. Van Tendeloo

    University of Antwerp

    3 shared publications
  • Yannick Willemen

    Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium

    3 shared publications

Latest Publications

  • The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy

    by Heleen H. Van Acker, Diana Campillo-Davo, Gils Roex, Maarten Versteven, Evelien L. Smits, Viggo F. Van Tendeloo


  • Open Access

    Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion

    by Heleen H. Van Acker, Sébastien Anguille, Hans De Reu, Zwi N. Berneman, Evelien L. Smits, Viggo F. Van Tendeloo

    Dendritic cell (DC) vaccination can be an effective post-remission therapy for acute myeloid leukemia (AML). Yet, current DC vaccines do not encompass the ideal stimulatory triggers for innate gamma delta (γδ) T cell anti-tumor activity. Promoting type 1 cytotoxic γδ T cells in patients with AML is, however, most interesting, considering these unconventional T cells are primed for rapid function and exert meaningful control over AML. In this work, we demonstrate that interleukin (IL)-15 DCs have the capacity to enhance the anti-tumoral functions of γδ T cells. IL-15 DCs of healthy donors and of AML patients in remission induce the upregulation of cytotoxicity-associated and co-stimulatory molecules on the γδ T cell surface, but not of co-inhibitory molecules, incite γδ T cell proliferation and stimulate their interferon-γ production in the presence of blood cancer cells and phosphoantigens. Moreover, the innate cytotoxic capacity of γδ T cells is significantly enhanced upon interaction with IL-15 DCs, both towards leukemic cell lines and allogeneic primary AML blasts. Finally, we address soluble IL-15 secreted by IL-15 DCs as the main mechanism behind the IL-15 DC-mediated γδ T cell activation. These results indicate that the application of IL-15-secreting DC subsets could render DC-based anti-cancer vaccines more effective through, among others, the involvement of γδ T cells in the anti-leukemic immune response.


  • Open Access

    CD56 in the Immune System: More Than a Marker for Cytotoxicity?

    by Heleen H. Van Acker, Anna Capsomidis, Evelien L. Smits, Viggo F. Van Tendeloo

    Over the past years, the phenotypic and functional boundaries distinguishing the main cell subsets of the immune system have become increasingly blurred. In this respect, CD56 (also known as NCAM) is a very good example. CD56 is the archetypal phenotypic marker of natural killers cells, but can actually be expressed by many more immune cells, including alpha beta (αβ) T cells, gamma delta (γδ) T cells, dendritic cells and monocytes. Common to all these CD56-expressing cell types are strong immunostimulatory effector functions, including T helper 1 cytokine production and an efficient cytotoxic capacity. Interestingly, both numerical and functional deficiencies and phenotypic alterations of the CD56+ immune cell fraction have been reported in patients with various infectious, autoimmune or malignant diseases. In this review, we will discuss our current knowledge on the expression and function of CD56 in the hematopoietic system, both in health and disease.


  • Open Access

    Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells

    by Heleen H. Van Acker, Ottavio Beretta, Sébastien Anguille, Lien De Caluwé, Angela Papagna, Johan M. Van Den Bergh, Yannick Willemen, Herman Goossens, Zwi N. Berneman, Viggo F. Van Tendeloo, et al.

    Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells


  • Open Access

    Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells

    by Heleen H. Van Acker, Sébastien Anguille, Yannick Willemen, Johan M. Van Den Bergh, Zwi N. Berneman, Eva Lion, Evelien L. Smits, Viggo F. Van Tendeloo

    Adoptive immunotherapy is gaining momentum to fight malignancies, whereby γδ T cells have received recent attention as an alternative cell source as to natural killer cells and αβ T cells. The advent of γδ T cells is largely due to their ability to recognize and target tumor cells using both innate characteristic and T cell receptor (TCR)-mediated mechanisms, their capacity to enhance the generation of antigen-specific T cell responses, and their potential to be used in an autologous or allogeneic setting. In this study, we explored the beneficial effect of the immunostimulatory cytokine interleukin (IL)-15 on purified γδ T cells and its use as a stimulatory signal in the ex vivo expansion of γδ T cells for adoptive transfer. The expansion protocol was validated both with immune cells of healthy individuals and acute myeloid leukemia patients. We report that the addition of IL-15 to γδ T cell cultures results in a more activated phenotype, a higher proliferative capacity, a more pronounced T helper 1 polarization, and an increased cytotoxic capacity of γδ T cells. Moreover γδ T cell expansion starting with peripheral blood mononuclear cells from healthy individuals and acute myeloid leukemia patients is boosted in the presence of IL-15, whereby the antitumor properties of the γδ T cells are strengthened as well. Our results support the rationale to explore the use of IL-15 in clinical adoptive therapy protocols exploiting γδ T cells.


  • Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials

    by Heleen H. Van Acker, Sébastien Anguille, Yannick Willemen, Evelien L. Smits, Viggo F. Van Tendeloo


  • Open Access

    Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy

    by Heleen H Van Acker, Sébastien Anguille, Viggo F Van Tendeloo, Eva Lion

    Gamma delta (γδ) T cells are the all-rounders of our immune-system with their major histocompatibility complex-unrestricted cytotoxicity, capacity to secrete immunosti-mulatory cytokines and ability to promote the generation of tumor antigen-specific CD8+ and CD4+ T cell responses. Dendritic cell (DC)-based vaccine therapy has the prospective to harness these unique features of the γδ T cells in the fight against cancer. In this review, we will discuss our current knowledge on DC-mediated γδ T cell activation and related opportunities for tumor immunologists.